Bioqual, Inc.
Bioqual, Inc. Fundamental Analysis
Bioqual, Inc. (BIOQ) shows weak financial fundamentals with a PE ratio of 74.02, profit margin of 0.97%, and ROE of 1.26%. The company generates $0.0B in annual revenue with N/A year-over-year growth of N/A.
Key Strengths
Areas of Concern
The stock receives a Fundamental Health Score of 20.9/100 based on profitability, valuation, growth, and balance sheet metrics. The F grade reflects weak fundamentals and significant financial concerns.
Fundamental Health Score
We analyze BIOQ's fundamental strength across five key dimensions:
Efficiency Score
WeakBIOQ struggles to generate sufficient returns from assets.
Valuation Score
ModerateBIOQ shows balanced valuation metrics.
Growth Score
ModerateBIOQ shows steady but slowing expansion.
Financial Health Score
ModerateBIOQ shows balanced financial health with some risks.
Profitability Score
ModerateBIOQ maintains healthy but balanced margins.
Key Financial Metrics
Is BIOQ Expensive or Cheap?
P/E Ratio
BIOQ trades at 74.02 times earnings. This suggests a premium valuation.
PEG Ratio
When adjusting for growth, BIOQ's PEG of 0.43 indicates potential undervaluation.
Price to Book
The market values Bioqual, Inc. at 0.94 times its book value. This may indicate undervaluation.
EV/EBITDA
Enterprise value stands at -5.55 times EBITDA. This is generally considered low.
How Well Does BIOQ Make Money?
Net Profit Margin
For every $100 in sales, Bioqual, Inc. keeps $0.97 as profit after all expenses.
Operating Margin
Core operations generate 0.27 in profit for every $100 in revenue, before interest and taxes.
ROE
Management delivers $1.26 in profit for every $100 of shareholder equity.
ROA
Bioqual, Inc. generates $0.62 in profit for every $100 in assets, demonstrating efficient asset deployment.
Following the Money - Real Cash Generation
Operating Cash Flow
Bioqual, Inc. generates limited operating cash flow of $2.20M, signaling weaker underlying cash strength.
Free Cash Flow
Bioqual, Inc. produces free cash flow of $1.83M, offering steady but limited capital for shareholder returns and expansion.
FCF Per Share
Each share generates $2.04 in free cash annually.
FCF Yield
BIOQ converts 5.45% of its market value into free cash.
Financial Ratios Analysis
Valuation Ratios
P/E Ratio
Price to earnings ratio
74.02
vs 25 benchmark
PEG Ratio
Price/earnings to growth ratio
0.43
vs 25 benchmark
P/B Ratio
Price to book value ratio
0.94
vs 25 benchmark
P/S Ratio
Price to sales ratio
0.72
vs 25 benchmark
Financial Health
Debt/Equity
Total debt to shareholders' equity
1.84
vs 25 benchmark
Current Ratio
Current assets to current liabilities
4.41
vs 25 benchmark
Efficiency Ratios
ROE
Return on equity percentage
0.01
vs 25 benchmark
ROA
Return on assets percentage
0.006
vs 25 benchmark
ROCE
Return on capital employed
0.002
vs 25 benchmark
How BIOQ Stacks Against Its Sector Peers
| Metric | BIOQ Value | Sector Average | Performance |
|---|---|---|---|
| P/E Ratio | 74.02 | 28.45 | Worse (Expensive) |
| ROE | 1.26% | 763.00% | Weak |
| Net Margin | 0.97% | -45265.00% (disorted) | Weak |
| Debt/Equity | 1.84 | 0.34 | Weak (High Leverage) |
| Current Ratio | 4.41 | 2795.60 | Strong Liquidity |
| ROA | 0.62% | -16588.00% (disorted) | Weak |
BIOQ outperforms its industry in 1 out of 6 key metrics, but lagging in P/E Ratio.
Historical Growth Performance
5-Year Growth Trajectory
This section reviews Bioqual, Inc.'s 5-year compound annual growth rate (CAGR) and compares its performance against the typical investment style of its industry.
Revenue CAGR
N/A
Industry Style: Defensive, Growth, Innovation
EPS CAGR
N/A
Industry Style: Defensive, Growth, Innovation
FCF CAGR
N/A
Industry Style: Defensive, Growth, Innovation